株探米国株
エドガーで原本を確認する
FALSE000101473900010147392026-07-292026-07-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
July 29, 2026
OPCH_Logo.jpg
OPTION CARE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-11993
05-0489664
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)
3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015
(Address of principal executive offices)
(312) 940-2443
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value per share OPCH Nasdaq Global Select Market


Item 2.02. Results of Operations and Financial Condition.
On July 29, 2026, Option Care Health, Inc. issued a press release reporting its second quarter 2026 financial results. A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.
The press release includes certain non-GAAP financial measures described therein. Reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.
The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Option Care Health, Inc.
Date:
July 29, 2026
 By: /s/ Meenal Sethna
Meenal Sethna
Chief Financial Officer

EX-99.1 2 exhibit991-q22026.htm EX-99.1 Document

Exhibit 99.1
 opch_logo.jpg
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026
BANNOCKBURN, IL., July 29, 2026 - Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2026.
Second Quarter 2026 Financial Highlights
(year-over-year comparisons unless otherwise noted)
•Net revenue of $1,442 million, up 1.9%
•GAAP net income of $53.9 million, up 6.7%
•GAAP diluted earnings per share of $0.35, up 12.9%
•Adjusted EBITDA of $117.5 million, up 3.0%
•Adjusted diluted earnings per share of $0.45, up 9.8%
•Cash provided by Q2 operating activities of $184 million
•Repurchased $150 million of outstanding shares in the quarter
John C. Rademacher, Chief Executive Officer, commented, “I’m proud of our team as we delivered strong second quarter results, reflecting solid operational execution and the positive impact of our 2026 strategic initiatives. Looking ahead, our results reinforce our confidence in the underlying fundamentals of the business, but there is still work to do as we further position the company for a sustainable long-term growth trajectory. Given the strength of our clinical platform, significant market opportunities and our operational focus, we believe we are well positioned to achieve our 2026 priorities while creating meaningful value for our patients, partners, and shareholders.”
Updated Full Year and Third Quarter 2026 Financial Guidance
For the full year 2026, Option Care Health expects the following:
•Net revenue of $5.675 billion to $5.775 billion
•Adjusted diluted earnings per share of $1.85 to $1.92
•Adjusted EBITDA of $480 million to $495 million
•Cash provided by operating activities of at least $320 million
For the third quarter 2026, Option Care Health expects the following compared to the second quarter 2026:
•Sequential net revenue growth in the low to mid single-digits
•Sequential Adjusted EBITDA growth in the mid single-digits


Conference Call
Option Care Health will host a conference call to discuss its results on Wednesday, July 29, 2026, at 8:30 a.m. ET. The conference call can be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available at the same web link for 90 days after the call.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members, including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
Investor Contact
Bob Okunski
Vice President, Investor Relations
investor.relations@optioncare.com


Forward-Looking Statements - Safe Harbor
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company may make regarding future revenues, future earnings, other future financial results, regulatory developments, market developments, new products and growth strategies and the effects of any of the foregoing on its future results of operations or financial condition.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws, regulations or trade policies applicable to its business model; loss of relationships with managed care organizations and other non-governmental third party payers; changes in the pharmaceutical industry, including limiting or discontinuing research, development, production and marketing of pharmaceuticals compatible with its services; changes in market conditions and receptivity to its services and offerings; and pending and future litigation or potential liability for claims not covered by insurance. For a detailed discussion of the risk factors that could affect its actual results, please refer to the risk factors identified in the Company's SEC reports as filed with the SEC.
Any forward-looking statement made by the Company in this press release is based only on information currently available to it and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted net income, Adjusted EBITDA and Adjusted diluted earnings per share ("EPS"), which are non-GAAP financial measures. These adjusted measures are not measurements of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, EPS, or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definitions of Adjusted net income, Adjusted EBITDA, and Adjusted diluted EPS may not be comparable to similarly titled non-GAAP financial measures reported by other companies. As defined by the Company: (i) Adjusted net income represents net income before intangible asset amortization expense, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, net of tax adjustments, (ii) Adjusted EBITDA represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, and (iii) Adjusted diluted EPS represents Adjusted net income divided by weighted average common shares outstanding, diluted. As part of restructuring, acquisition, integration and other expenses, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, certain litigation expenses and reserves related to acquired businesses, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that these adjusted measures provide useful supplemental information regarding the performance of Option Care Health’s business operations and facilitate comparisons to the Company’s historical operating results. The Company has not reconciled Adjusted EBITDA guidance to net income or Adjusted diluted EPS guidance to GAAP diluted EPS as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. Full reconciliations of each historical adjusted measure to the most comparable GAAP financial measure are set forth below.



Schedule 1
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)
June 30, 2026 December 31, 2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 193,767  $ 232,624 
Accounts receivable, net 511,507  473,566 
Inventories 399,605  471,149 
Prepaid expenses and other current assets 95,713  87,629 
Total current assets 1,200,592  1,264,968 
NONCURRENT ASSETS:
Property and equipment, net 140,408  139,236 
Intangible assets, net 20,229  21,897 
Referral sources, net 270,410  287,281 
Goodwill 1,606,743  1,606,743 
Other noncurrent assets 140,395  135,644 
Total noncurrent assets 2,178,185  2,190,801 
TOTAL ASSETS $ 3,378,777  $ 3,455,769 
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable $ 639,767  $ 639,829 
Other current liabilities 179,710  189,519 
Total current liabilities 819,477  829,348 
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion 1,152,040  1,154,052 
Other noncurrent liabilities 147,362  145,976 
Total noncurrent liabilities 1,299,402  1,300,028 
Total liabilities 2,118,879  2,129,376 
STOCKHOLDERS’ EQUITY 1,259,898  1,326,393 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 3,378,777  $ 3,455,769 



Schedule 2
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
Three Months Ended June 30, Six Months Ended June 30,
2026 2025 2026 2025
NET REVENUE $ 1,442,400  $ 1,416,085  $ 2,793,054  $ 2,749,057 
COST OF REVENUE 1,175,149  1,147,042  2,263,789  2,216,962 
GROSS PROFIT 267,251  269,043  529,265  532,095 
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses 161,110  167,467  331,065  330,275 
Restructuring, acquisition, integration and other 3,549  2,625  8,156  7,935 
Depreciation and amortization expense 17,452  16,241  32,359  31,987 
Total operating expenses 182,111  186,333  371,580  370,197 
OPERATING INCOME 85,140  82,710  157,685  161,898 
OTHER INCOME (EXPENSE):
Interest expense, net (14,020) (14,447) (27,324) (27,678)
Other, net 2,867  598  4,629  (1,803)
Total other (expense) income (11,153) (13,849) (22,695) (29,481)
INCOME BEFORE INCOME TAXES 73,987  68,861  134,990  132,417 
INCOME TAX EXPENSE 20,074  18,338  35,734  35,152 
NET INCOME $ 53,913  $ 50,523  $ 99,256  $ 97,265 
Earnings per share, basic $ 0.35  $ 0.31  $ 0.64  $ 0.59 
Earnings per share, diluted $ 0.35  $ 0.31  $ 0.64  $ 0.59 
Weighted average common shares outstanding, basic 152,931  162,931  154,782  164,188 
Weighted average common shares outstanding, diluted 153,485  164,133  155,772  165,402 



Schedule 3
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)
Six Months Ended June 30,
2026 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 99,256  $ 97,265 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense 34,037  33,326 
Other adjustments 31,535  35,857 
Changes in operating assets and liabilities:
Accounts receivable, net (37,941) (61,392)
Inventories 71,544  (12,718)
Prepaid expenses and other current assets (9,958) 17,606 
Accounts payable 2,610  (27,904)
Accrued compensation and employee benefits (4,188) 8,730 
Other (15,410) (7,651)
Net cash provided by operating activities 171,485  83,119 
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment (20,123) (18,466)
Business acquisitions, net of cash acquired —  (117,247)
Other investing activities (877) — 
Net cash used in investing activities (21,000) (135,713)
CASH FLOWS FROM FINANCING ACTIVITIES:
Purchase of company stock and related excise taxes (170,545) (152,429)
Other financing activities (18,797) (8,724)
Net cash used in financing activities (189,342) (161,153)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (38,857) (213,747)
Cash and cash equivalents - beginning of period 232,624  412,565 
CASH AND CASH EQUIVALENTS - END OF PERIOD $ 193,767  $ 198,818 



Schedule 4
OPTION CARE HEALTH, INC.
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
Three Months Ended June 30, Six Months Ended June 30,
2026 2025 2026 2025
Net income $ 53,913  $ 50,523  $ 99,256  $ 97,265 
Interest expense, net 14,020  14,447  27,324  27,678 
Income tax expense 20,074  18,338  35,734  35,152 
Depreciation and amortization expense 18,382  16,953  34,037  33,326 
EBITDA 106,389  100,261  196,351  193,421 
EBITDA adjustments
Stock-based incentive compensation expense 8,382  10,712  18,581  19,513 
Restructuring, acquisition, integration and other (1) 2,711  3,045  7,320  12,850 
Adjusted EBITDA $ 117,482  $ 114,018  $ 222,252  $ 225,784 
Net income $ 53,913  $ 50,523  $ 99,256  $ 97,265 
Intangible asset amortization expense 9,269  9,297  18,539  18,394 
Stock-based incentive compensation expense 8,382  10,712  18,581  19,513 
Restructuring, acquisition, integration and other (1) 2,711  3,045  7,320  12,850 
Total pre-tax adjustments 20,362  23,054  44,440  50,757 
Tax adjustments (2) (5,589) (6,109) (11,777) (13,451)
Adjusted net income $ 68,686  $ 67,468  $ 131,919  $ 134,571 
Earnings per share, diluted $ 0.35  $ 0.31  $ 0.64  $ 0.59 
Adjusted earnings per share, diluted $ 0.45  $ 0.41  $ 0.85  $ 0.81 
Weighted average common shares outstanding, diluted 153,485  164,133  155,772  165,402 
(1) Restructuring, acquisition, integration and other includes $3,549 and $8,156 of operating expenses for the three and six months ended June 30, 2026, respectively. Restructuring, acquisition, integration and other includes $2,625 and $7,935 of operating expenses for the three and six months ended June 30, 2025, respectively.
(2) Tax adjustments for the three and six months ended June 30, 2026 and 2025 includes the estimated income tax effect on non-GAAP adjustments based on the effective tax rate.